2Li JJ, Fang CH. C-reactive protein is not only an inflammatory marker but also a direct cause of cardiovascular disease. Med Hypotheses, 2004.62:252-256.
3Li JJ. Silent myocardiat ischemia may be related to inflammatory response. MedHypotheses,2004,62:252-256.
4Ridker PM. High-sensitivity C-reactive protein:potential adjunct for global risk assessmentin the primary primary prevention of cardiovascular Circulation,2001,103:1813-1818.
6Venugopa L, Kumar S, Devara J, et al. Effect of C-reactive protein on vascular cell: evidence for a proinflammatory, proath erogenic role. Nephrol Hypertens,2005,14(1):33-37.
7Mold C, gewurz H, Du Clos TW. Regulation of complement activation by C-reactive protein. Immunopharmacology, 1999,42:23-30.
7Schonbeck U, Sukhova GK, Shimizu K, et al. Inhibition of CD40 signaling limits evolution of established atherosclerosis in mice. Proc Nail Acad Sci USA, 2000, 97: 7458-7463.
8Lutgens E, Cleutjens KBJM, Heeneman S, et al. Both early and delayed anti-CD40L antibody treatment induces a stable plaque phenotype. Proc Nail Aced Sci. USA, 2000, 97: 7464-7469.
9Kai H,Ikeda H, Yasukawa H, et al. Perpherial blood levels of matrix metalloproteinase-2 and 9 are evelated In patients with acute coronary sndrome. J Am Coll Cardiol , 1998,32:368-372.
10Taku T, Toshio H, Hatsuyo K, et al. Cerivastatin, a HMG-CoA Reductase Inhibitor, Improves Endothelial Function In Elderly Diabetics winthin 3 days. Circulation, 2001,104:376-379.
